Med Bull Sisli Etfal Hosp. 2006; 40(4): 43-46

Insulin-like growth factor (IGF-I) and CA 15-3 values in primary breast cancer patients

Nihal Yücel, Þebnem Ciðerli, Berna Aslan, Cazibe Batý, Nezaket Eren
Biochemistry and Clinical Biochemistry Laboratory, Þiþli Etfal Training and Research Hospital, Istanbul Turkey

Objective: In this study, we investigated the the efficacy of insulin-like growth factor (IGF-I) on the diagnosis of primary breast cancer when measured along with carbonhydrate antigen 15- 3(CA 15-3).
Study Design: 40 primary breast cancer patient consulted in the General Surgery Department of Istanbul University Cerrahpasa Medical Faculty and 30 healthy women were included in the study. The patients were divided into two groups as premenapausal and postmenopausal. IGF-1 and CA 15-3 measurement were performed with chemiluminescence method in Liaison immunoassay analyser.
br> Results: The mean plasma IGF-I levels was 140,8±90,6 ng/ml in premenopausal patient group, and 109,9±48,6 ng/ml in postmenopausal patient group. In control group, IGF-I levels were 126,6±40,7 ng/ml in premenopausal and 110,3+60,4 ng/ml in postmenopausal individuals. There was not any difference between two groups (p-0,9, and p=0,5 respectively). In beast cancer patients, the mean serum Ca 15-3 levels was 24,8±34,07 Ulml. Only 4 patients (%10) had results over 30 Ulml which was accepted as cut-off value. The mean serum Ca 15-3 values in control group was 17,8±8,0 Ulml which was not significantly different from the patients results (p-0.1). 0
Conclusions: Finally, we concluded that IGF-I alone or along with CA15-3 is not a useful screening test for the diagnosis of breast cancer.

Keywords: Breast cancer, insulin-like growth factor (IGF-I), carbonhydrate antigen 15-3 (CA 15-3).

---

Primer meme kanserli hastalarýn serum insülin- benzeri büyüme faktörü-1 (IGF-I) VE CA 15-3 seviyelerinin araþtýrýlmasý

Nihal Yücel, Þebnem Ciðerli, Berna Aslan, Cazibe Batý, Nezaket Eren
Þiþli Etfal Eðitim ve Araþtýrma Hastanesi, Biyokimiya ve Klinik Biokimiya Laboratuvarý, Ýstanbul

Amaç: Primer meme kanseri tanýsýnýn konmasýnda insülin benzeri büyüme faktörü (insulin-like growth factor - IGF-I)‘in karbonhidrat antijen 15-3 (CA 15-3) ile birlikte deðerlendirilmesinin faydalý olup olmayacaðýný araþtýrdýk.
Gereç ve Yöntem: Çalýþmamýza Ýstanbul Üniversitesi Ýstanbul Týp Fakültesi Cerrahi Servisine baþvuran 40 tane primer meme kanserli kadýn hasta ile 30 tane hiçbir yakýnmasý olmayan saðlýklý kiþi dahil edildi. Hastalarýmýzý premenopozal ve postmenopozal olarak iki gruba ayýrdýk. IGF-I ve CA 15-3 ölçümü Liaison hormon cihazýnda kemilüminesans yöntemi ile yapýldý.
Bulgular: Hastalarýn premenopoz grubunda IGF-I seviyesi ortalama I40,8±90,6 ng/ml, postmenopoz grubunda IGF-I seviyeleri ortalama 109,9±48,6 ng/ml olarak bulundu. Kontrol gruplarýnda premenopozal olanlarýn IGF-I deðerleri ortalama 126,6±40,7 ng/ml postmenopozal olanlarýn ortalama 110,3+60,4 ng/ml olarak ölçüldü ve istatistiksel açýdan aralarýnda bir fark bulunamadý (sýrasýyla p=0,9 p-0,5). Meme kanserli hastalardaki serum CA 15-3 düzeyi ortalama 24,8±34,07 U/ml olarak ölçüldü. Toplam 4 hastamýzýn (%10) sonuçlarý kit normali olan ve sýnýr deðer olarak kabul ettiðimiz 30 U/ml‘yi aþabildi. Kontrol grubunda ölçülen serum CA 15-3 düzeyleri ise ortalama 17,8±8,0 U/ml olarak ölçüldü. Primer meme kanserli hastalarýn CA 15-3 ölçümlerinde de kontrol grubu ile bir fark bulunamadý (p=0,l).
Sonuçlar: Sonuç olarak IGF-I ölçümlerinin primer meme kanserli hastalarýn tanýsýnda tarama testi olarak, hem tek baþýna hem CA 15-3 ile birlikte faydalý olmayacaðý kanýsýna vardýk.

Anahtar Kelimeler: Meme kanseri, insülin benzeri büyüme faktörü (IGF-I), karbonhidrat antijen 15-3 (CA 15-3).

---

CITE